NCT04856059 Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI
| NCT ID | NCT04856059 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Fabry Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-06-15 |
| Primary Completion | 2029-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2021-06-15 with a primary completion date of 2029-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.
Eligibility Criteria
Inclusion Criteria: * Fabry disease; * Age ≥ 18 years. Exclusion Criteria: * History of myocardial infarction; * Contraindication to MRI.
Contact & Investigator
Kate Hanneman
PRINCIPAL INVESTIGATOR
University Health Network, Toronto
Frequently Asked Questions
Who can join the NCT04856059 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fabry Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04856059 currently recruiting?
Yes, NCT04856059 is actively recruiting participants. Contact the research team at kate.hanneman@uhn.ca for enrollment information.
Where is the NCT04856059 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT04856059 clinical trial?
NCT04856059 is sponsored by University Health Network, Toronto. The principal investigator is Kate Hanneman at University Health Network, Toronto. The trial plans to enroll 300 participants.